Add BrightSurf on Google Email

Massachusetts General Hospital


Research calls for changes to state law requiring child protective services to be notified when medications for opioid use disorder are used during pregnancy

Research finds that Massachusetts' policy mandating reporting to child protective services for prenatal opioid use disorder (MOUD) exposure can be stigmatizing and lead to medical decision-making changes. The study calls for changing the law to uncouple treatment decisions from mandated reporting during the perinatal period.

SourceMassachusetts General Hospital·JournalMaternal and Child Health Journal·DateMay 31, 2023

Research spotlight: a conversational artificial intelligence program can generate credible medical information in response to common patient questions

A study found that a conversational artificial intelligence program can generate easy-to-understand, scientifically adequate answers to common patient questions about colonoscopy. The program outperformed human ratings in terms of scientific adequacy and satisfaction with the answers.

SourceMassachusetts General Hospital·JournalGastroenterology·DateMay 17, 2023

Study finds alcohol-related liver disease soared in nearly all states during the pandemic, with one race particularly affected

Alcohol consumption increased substantially across US during COVID-19 pandemic, particularly among American Indian and Alaska Native populations, leading to a six-fold increase in deaths from alcohol-associated liver disease compared to white people. The study highlights the need for urgent action by public policy leaders to address th...

SourceMassachusetts General Hospital·JournalJAMA Health Forum·DateApr 21, 2023

Researchers uncover a protein deficiency in neurons of patients with neurodegenerative diseases that could be targeted by new gene therapy approach

A team of researchers has discovered a protein deficiency in the neurons of patients with neurodegenerative diseases, such as ALS and Alzheimer's disease. They have developed an approach to fix this deficiency using antisense oligonucleotides that can correct abnormal RNA processing and restore stathmin-2 protein levels.

SourceMassachusetts General Hospital·JournalScience·DateMar 20, 2023

Mass General researchers discover the role of intestinal fibrosis in inflammatory bowel disease

Researchers at Mass General Hospital have found that intestinal fibrosis plays a critical role in the progression of inflammatory bowel disease (IBD), affecting the growth and differentiation of intestinal stem cells. The study suggests targeting mechanosensing pathways may offer an attractive therapeutic strategy for IBD.

SourceMassachusetts General Hospital·JournalGastroenterology·TypeExperimental study·DateMar 8, 2023

New Insights by Mass General on the molecular mechanism of hydrocephalus could lead to the first-ever non-surgical treatment

Researchers at Mass General Hospital have discovered a novel molecular mechanism responsible for acquired hydrocephalus, which could lead to the development of a non-surgical treatment. The study found that an anti-inflammatory drug, rapamycin, can target the pathway that causes swelling of the brain ventricles in patients with hydroce...

Risk of thrombotic events should not exclude transgender people from receiving hormone therapy, according to new guidance

Research suggests that withholding gender-affirming hormone therapy from transgender individuals may have negative mental and physical effects. A new study provides comprehensive guidance for assessing, managing, and treating venous thromboembolism in transgender patients receiving feminizing hormone therapy.

SourceMassachusetts General Hospital·JournalEndocrine Practice·TypeSystematic review·DateMar 6, 2023

A Mass General team is the first to trace a rare smooth muscle disorder to a single mutation in a non-coding gene

A Mass General team has identified a single mutation in a non-coding gene, MIR145-5p, as the source of multisystemic smooth muscle dysfunction syndrome, which had gone undiagnosed in a child for years. The discovery enabled physicians to initiate treatment and lessen the risk of future strokes.

SourceMassachusetts General Hospital·JournalJournal of Clinical Investigation·DateFeb 28, 2023

New insights into how blood pressure drug may benefit patients with locally advanced pancreatic cancer

Researchers found that combining losartan with chemotherapy and chemoradiation improves blood vessel normalization, immune cell maturation, and reduces immunosuppression in patients with locally advanced pancreatic cancer. This combination therapy may potentiate the benefits of other anti-cancer treatments.

SourceMassachusetts General Hospital·JournalClinical Cancer Research·DateFeb 15, 2023

Nasal drops of polysulfides may prevent a serious side effect—paralysis of the lower body—after surgery to repair the aorta

Researchers have found that nasal drops of chemical compounds called polysulfides may prevent serious side effects of aortic surgery, such as paralysis of the lower body. In a mouse model of paraplegia after aortic surgery, intranasal administration of polysulfides inhibited damage to spinal cord motor neurons and prevented paraplegia.

SourceMassachusetts General Hospital·JournalRedox Biology·DateFeb 6, 2023

Blood pressure drug may prevent immunotherapy-induced brain swelling in patients with glioblastoma

Researchers at Massachusetts General Hospital found that losartan can reduce the expression of inflammatory enzymes responsible for immunotherapy-related edema. The study suggests that losartan may allow patients to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateFeb 2, 2023

Immunotherapy combined with targeted therapy for colorectal cancer yields promising outcomes for patients

A phase 2 clinical trial combining immunotherapy and targeted therapy showed a 24.3% confirmed response rate and 5-month median progression-free survival among patients with BRAF V600 mutations. The treatment also demonstrated increased durability, with 57% of patients remaining on treatment for more than 6 months.

SourceMassachusetts General Hospital·JournalNature Medicine·TypeExperimental study·DateJan 26, 2023

Investigational drug may combat brain tumors by targeting cancer cells' fat production

A new study led by Massachusetts General Hospital researchers reveals that an investigational drug called YTX-7739 can delay the growth of brain tumors and increase their sensitivity to conventional chemotherapy. The drug works by inhibiting de novo lipid synthesis, a process used by cancer cells for energy production.

SourceMassachusetts General Hospital·JournalScience Translational Medicine·DateJan 18, 2023

Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations

Researchers at Massachusetts General Hospital created a new class of technologies called CRISPR-associated transposases (CASTs) to overcome diverse disease-causing mutations. The optimized approach improves product purity and genome-wide specificity, offering a potential solution for inserting entire genes into the genome.

SourceMassachusetts General Hospital·JournalNature Biotechnology·TypeExperimental study·DateJan 17, 2023

Clinical trial results indicate low rate of adverse events associated with implanted brain computer interface

A new clinical trial report reveals that brain-computer interface implants are associated with a low rate of adverse events, similar to those experienced by patients with other chronic medical conditions. The study, which followed 14 participants for an average of 872 days, found no serious adverse events or device removals.

SourceMassachusetts General Hospital·JournalNeurology·TypeObservational study·DateJan 13, 2023

Mathematical model predicts long-term effectiveness of COVID-19 vaccine booster doses in different patient populations

A mathematical model predicts the long-term effectiveness of COVID-19 vaccine booster doses in various patient populations, including those with healthy immune systems and cancer patients. The model suggests that robust antibody-based responses can be achieved through booster doses, but may wane quickly in immunosuppressed individuals.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·TypeComputational simulation/modeling·DateJan 9, 2023

New oral compound developed by Mass General researchers may help prevent and treat osteoporosis

Researchers at Massachusetts General Hospital have identified a promising oral compound that stimulates bone formation in mice, increasing blood levels of calcium and vitamin D. The compound, SK-124, boosts bone formation and mass without short-term toxicity, offering new hope for preventing and treating osteoporosis.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateDec 6, 2022

Artificial intelligence approach may help identify melanoma survivors who face a high risk of cancer recurrence

A team from Massachusetts General Hospital developed an AI-based method to predict which patients with early-stage melanoma are most likely to experience a recurrence. Machine learning algorithms extracted predictive signals from clinicopathologic features, including tumor thickness and rate of cancer cell division.

SourceMassachusetts General Hospital·Journalnpj Precision Oncology·TypeComputational simulation/modeling·DateOct 31, 2022

How severe is the SARS-CoV-2 Omicron BA.2 subvariant compared with earlier variants?

Researchers at Massachusetts General Hospital analyzed data from March 2020 to June 2022 to assess the severity of SARS-CoV-2 Omicron BA.2 subvariant compared to earlier variants. The study found that BA.2 was associated with lower mortality rates and reduced need for hospitalizations, invasive ventilation, and intensive care admissions.

SourceMassachusetts General Hospital·JournalJAMA Network Open·TypeData/statistical analysis·DateOct 26, 2022

SARS-CoV-2 placentitis, and how maternal COVID-19 vaccination could prevent stillbirth

A recent literature review found that vaccination against SARS-CoV-2 can effectively prevent adverse conditions such as stillbirth and infant death. Pregnant women with COVID-19 have an increased risk for stillbirth compared to uninfected women, and those who vaccinate can more effectively prevent these events.

SourceMassachusetts General Hospital·JournalAJOG Global Reports·TypeLiterature review·DateOct 21, 2022

After cardiac arrest, does sedation improve the chance of surviving and regaining normal brain function?

Researchers at Massachusetts General Hospital found that sedating patients after cardiac arrest can improve their chances of survival and regaining normal brain function. The study, conducted in mice, showed that sedatives like propofol and dexmedetomidine improved survival rates compared to those who received no sedation.

SourceMassachusetts General Hospital·JournalAnesthesiology·TypeExperimental study·DateOct 18, 2022

Antibody-based therapy eliminates circulating tumor cells in mouse models of breast and pancreatic cancer

Researchers developed an antibody-based treatment that targets cadherins on circulating tumor cells, eliminating them in mouse models of breast and pancreatic cancer. The therapy shows promise in preventing cancer metastasis, a leading cause of cancer-related deaths.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateOct 17, 2022